Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2005 Oct;76(10):1377–1381. doi: 10.1136/jnnp.2004.048504

Epstein-Barr virus and disease activity in multiple sclerosis

D Buljevac 1, G J J van Doornum 1, H Flach 1, J Groen 1, A Osterhaus 1, W Hop 1, P A van Doorn 1, F G A van der Meche 1, R Hintzen 1
PMCID: PMC1739347  PMID: 16170080

Abstract

Objectives: To study in relapsing–remitting (RR) multiple sclerosis (MS) whether exacerbations and brain activity as measured by magnetic resonance imaging (MRI) are associated with plasma levels of anti-Epstein Barr (EBV) antibodies and EBV DNA.

Methods: This was a prospective study with 73 RR MS patients followed for an average of 1.7 years with frequent neurological examination and blood sampling. Antibodies to various EBV proteins were measured by ELISA and plasma EBV DNA was measured by PCR.

Results: All MS patients had IgG antibodies to EBV (viral capsid antigen (VCA) and/or EBV nuclear antigen (EBNA)), irrespective whether samples were taken at stable disease or exacerbation. A significantly elevated percentage of the patients (48%) had antibodies against EBV antigens (early antigen, EA) that indicate active viral replication, compared with the age matched healthy controls (25%). Antibodies against a control herpesvirus, cytomegalovirus, were similar between the two groups. The percentage of EA positive individuals and EA titres did not differ between stable disease or exacerbation. Anti-VCA IgM was positive in three cases, unrelated to disease activity. Using a highly sensitive PCR on 51 samples taken at exacerbation visits, only three patients were found to have one timepoint with viraemia, and this viraemia was unrelated to disease activity. Of special note was the fact that anti-EA seropositive patients remained seropositive during follow up, with stable titres over time. We hypothesised that these patients may constitute a subgroup with higher disease activity, due to the triggering effect of a chronic attempt of the virus to reactivate. The EA positive group did not differ from the EA negative with respect to clinical disease activity or other characteristics. However, in the EA positive group, analysis with gadolinium enhanced MRI indicated more MRI disease activity.

Conclusions: There was no evidence for increased clinical disease activity in the subgroup of MS patients with serological signs of EBV reactivation. However, the observation that chronic EBV reactivation may be associated with increased inflammatory activity as assessed by gadolinium enhanced MRI lesions should be reproduced in a larger and independent dataset.

Full Text

The Full Text of this article is available as a PDF (89.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ascherio A., Munch M. Epstein-Barr virus and multiple sclerosis. Epidemiology. 2000 Mar;11(2):220–224. doi: 10.1097/00001648-200003000-00023. [DOI] [PubMed] [Google Scholar]
  2. Ascherio A., Munger K. L., Lennette E. T., Spiegelman D., Hernán M. A., Olek M. J., Hankinson S. E., Hunter D. J. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA. 2001 Dec 26;286(24):3083–3088. doi: 10.1001/jama.286.24.3083. [DOI] [PubMed] [Google Scholar]
  3. Bachmann S., Kesselring J. Multiple sclerosis and infectious childhood diseases. Neuroepidemiology. 1998;17(3):154–160. doi: 10.1159/000026167. [DOI] [PubMed] [Google Scholar]
  4. Buisson M., Fleurent B., Mak M., Morand P., Chan L., Ng A., Guan M., Chin D., Seigneurin J. M. Novel immunoblot assay using four recombinant antigens for diagnosis of Epstein-Barr virus primary infection and reactivation. J Clin Microbiol. 1999 Aug;37(8):2709–2714. doi: 10.1128/jcm.37.8.2709-2714.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Buljevac D., Flach H. Z., Hop W. C. J., Hijdra D., Laman J. D., Savelkoul H. F. J., van Der Meché F. G. A., van Doorn P. A., Hintzen R. Q. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain. 2002 May;125(Pt 5):952–960. doi: 10.1093/brain/awf098. [DOI] [PubMed] [Google Scholar]
  6. Cohen J. I. Epstein-Barr virus infection. N Engl J Med. 2000 Aug 17;343(7):481–492. doi: 10.1056/NEJM200008173430707. [DOI] [PubMed] [Google Scholar]
  7. Gorgievski-Hrisoho M., Hinderer W., Nebel-Schickel H., Horn J., Vornhagen R., Sonneborn H. H., Wolf H., Siegl G. Serodiagnosis of infectious mononucleosis by using recombinant Epstein-Barr virus antigens and enzyme-linked immunosorbent assay technology. J Clin Microbiol. 1990 Oct;28(10):2305–2311. doi: 10.1128/jcm.28.10.2305-2311.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Haahr S., Koch-Henriksen N., Møller-Larsen A., Eriksen L. S., Andersen H. M. Increased risk of multiple sclerosis after late Epstein-Barr virus infection: a historical prospective study. Mult Scler. 1995 Jun;1(2):73–77. doi: 10.1177/135245859500100203. [DOI] [PubMed] [Google Scholar]
  9. Henle W., Henle G., Zajac B. A., Pearson G., Waubke R., Scriba M. Differential reactivity of human serums with early antigens induced by Epstein-Barr virus. Science. 1970 Jul 10;169(3941):188–190. doi: 10.1126/science.169.3941.188. [DOI] [PubMed] [Google Scholar]
  10. Holmøy Trygve, Vartdal Frode. Cerebrospinal fluid T cells from multiple sclerosis patients recognize autologous Epstein-Barr virus-transformed B cells. J Neurovirol. 2004 Feb;10(1):52–56. doi: 10.1080/13550280490261671. [DOI] [PubMed] [Google Scholar]
  11. Höllsberg P., Hansen H. J., Haahr S. Altered CD8+ T cell responses to selected Epstein-Barr virus immunodominant epitopes in patients with multiple sclerosis. Clin Exp Immunol. 2003 Apr;132(1):137–143. doi: 10.1046/j.1365-2249.2003.02114.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Lang Heather L. E., Jacobsen Helle, Ikemizu Shinji, Andersson Christina, Harlos Karl, Madsen Lars, Hjorth Peter, Sondergaard Leif, Svejgaard Arne, Wucherpfennig Kai. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat Immunol. 2002 Sep 3;3(10):940–943. doi: 10.1038/ni835. [DOI] [PubMed] [Google Scholar]
  13. Levin Lynn I., Munger Kassandra L., Rubertone Mark V., Peck Charles A., Lennette Evelyne T., Spiegelman Donna, Ascherio Alberto. Multiple sclerosis and Epstein-Barr virus. JAMA. 2003 Mar 26;289(12):1533–1536. doi: 10.1001/jama.289.12.1533. [DOI] [PubMed] [Google Scholar]
  14. Li J. S., Zhou B. S., Dutschman G. E., Grill S. P., Tan R. S., Cheng Y. C. Association of Epstein-Barr virus early antigen diffuse component and virus-specified DNA polymerase activity. J Virol. 1987 Sep;61(9):2947–2949. doi: 10.1128/jvi.61.9.2947-2949.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Martyn C. N., Cruddas M., Compston D. A. Symptomatic Epstein-Barr virus infection and multiple sclerosis. J Neurol Neurosurg Psychiatry. 1993 Feb;56(2):167–168. doi: 10.1136/jnnp.56.2.167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Munch M., Hvas J., Christensen T., Møller-Larsen A., Haahr S. The implications of Epstein-Barr virus in multiple sclerosis--a review. Acta Neurol Scand Suppl. 1997;169:59–64. doi: 10.1111/j.1600-0404.1997.tb08151.x. [DOI] [PubMed] [Google Scholar]
  17. Myhr K. M., Riise T., Barrett-Connor E., Myrmel H., Vedeler C., Grønning M., Kalvenes M. B., Nyland H. Altered antibody pattern to Epstein-Barr virus but not to other herpesviruses in multiple sclerosis: a population based case-control study from western Norway. J Neurol Neurosurg Psychiatry. 1998 Apr;64(4):539–542. doi: 10.1136/jnnp.64.4.539. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Niesters H. G., van Esser J., Fries E., Wolthers K. C., Cornelissen J., Osterhaus A. D. Development of a real-time quantitative assay for detection of Epstein-Barr virus. J Clin Microbiol. 2000 Feb;38(2):712–715. doi: 10.1128/jcm.38.2.712-715.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Operskalski E. A., Visscher B. R., Malmgren R. M., Detels R. A case-control study of multiple sclerosis. Neurology. 1989 Jun;39(6):825–829. doi: 10.1212/wnl.39.6.825. [DOI] [PubMed] [Google Scholar]
  20. Reiber H., Ungefehr S., Jacobi C. The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis. Mult Scler. 1998 Jun;4(3):111–117. doi: 10.1177/135245859800400304. [DOI] [PubMed] [Google Scholar]
  21. SCHUMACHER G. A., BEEBE G., KIBLER R. F., KURLAND L. T., KURTZKE J. F., MCDOWELL F., NAGLER B., SIBLEY W. A., TOURTELLOTTE W. W., WILLMON T. L. PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS. Ann N Y Acad Sci. 1965 Mar 31;122:552–568. doi: 10.1111/j.1749-6632.1965.tb20235.x. [DOI] [PubMed] [Google Scholar]
  22. Steven N. M., Annels N. E., Kumar A., Leese A. M., Kurilla M. G., Rickinson A. B. Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response. J Exp Med. 1997 May 5;185(9):1605–1617. doi: 10.1084/jem.185.9.1605. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Sumaya C. V., Myers L. W., Ellison G. W., Ench Y. Increased prevalence and titer of Epstein-Barr virus antibodies in patients with multiple sclerosis. Ann Neurol. 1985 Apr;17(4):371–377. doi: 10.1002/ana.410170412. [DOI] [PubMed] [Google Scholar]
  24. Wandinger K., Jabs W., Siekhaus A., Bubel S., Trillenberg P., Wagner H., Wessel K., Kirchner H., Hennig H. Association between clinical disease activity and Epstein-Barr virus reactivation in MS. Neurology. 2000 Jul 25;55(2):178–184. doi: 10.1212/wnl.55.2.178. [DOI] [PubMed] [Google Scholar]
  25. Wekerle Hartmut, Hohlfeld Reinhard. Molecular mimicry in multiple sclerosis. N Engl J Med. 2003 Jul 10;349(2):185–186. doi: 10.1056/NEJMcibr035136. [DOI] [PubMed] [Google Scholar]
  26. Wucherpfennig K. W., Strominger J. L. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell. 1995 Mar 10;80(5):695–705. doi: 10.1016/0092-8674(95)90348-8. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES